Insys Therapeutics
Work in HR? Unlock Free Profile

Insys Therapeutics Reviews

3 Reviews
3 Reviews

Recommend to a friend
Approve of CEO
(no image)
Michael L. Babich
0 Ratings
  1. 5 people found this helpful  


    Former Employee - Anonymous Employee
    Former Employee - Anonymous Employee

    I worked at Insys Therapeutics


    very few positive things to say


    management is crooked and expects off label promotion

Insys Therapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Edit Profile
Headquarters Phoenix, AZ
Size 150 to 499 Employees
Founded Unknown
Type Company - Public (INSY)
Industry Biotech & Pharmaceuticals
Revenue $50 to $100 million (USD) per year

Insys Therapeutics aims to take the rough edges off of chemo and cancer pain. The drug development company is focused on treating side effects of chemotherapy, as well as therapies for pain management. Its lead candidate is a fast-acting oral spray version of cancer pain drug Fentanyl. Its Dronabinol candidate is a generic capsule form of Marinol (a synthetic version of the active chemical in marijuana) for treatment of chemotherapy-induced nausea and vomiting. Both drugs are in late stage development awaiting FDA approval. All of the company's drug candidates are... More

Worked for Insys Therapeutics? Contribute to the Community!